** Shares of drug developer Summit Therapeutics rise ~4% to $18.88
** Brokerage Truist Securities starts coverage on SMMT with "buy" rating; PT $35
** PT represents a 92.7% upside to the stock's last close
** Last year, SMMT's ivonescimab showed better survival rates among lung cancer patients compared with Merck's Keytruda, world's biggest selling drug, in a late-stage study in China
** Brokerage estimates the drug could generate $7 bln in peak sales, primarily from lung cancer
** SMMT could also be a potential acquisition target - Truist Securities
** SMMT jumped ~580% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.